2013-16 C.1: Unitaid 2013-2016 Strategic Objectives and grant relevance Strategic objective Market shortcoming sought to be Description of project aims addressed through the project and alignment with Strategic Objective/ market shortcoming 1: Increase access to Affordability: Traditional HIV diagnostics Within the project aims, simple, performed in sophisticated laboratory operational research was to be diagnostics for settings are unaffordable for conducted on feasibility, settings. acceptability, sustainability, HIV/AIDS, TB, and and affordability of POC malaria Quality Absence of information on testing and laboratory-based quality of newer POC diagnostics. tools to determine optimal Traditional, Acceptability/ Adaptability: implementation approaches laboratory-based products are ill-adapted across a range of settings. In for low-resource settings because they addition, informal assessments are complicated to use and maintain, and on the quality of the products require sophisticated infrastructure and were to be conducted. As skilled technicians. Newer POC such, the focus of the project diagnostics currently on the market allow was on acceptability/ for more decentralized testing but many adaptability and delivery, are still too complicated for use in although it also touched upon remote settings by unskilled workers. affordability and quality. Delivery: Slow and insufficient uptake of both traditional laboratory-based and newer POC diagnostics. 2: Increase access to Delivery: Few children are initiated on Project indirectly contributed affordable, adapted HIV treatment to 18 months of age towards this objective by paediatric as recommended. aiming to improve access to EID. medicines to HIV/AIDS, tuberculosis, and malaria 3: Increase access to Affordability: High prices of existing Project indirectly contributed emerging medicines products to this objective by increasing and/or regimens as the understanding of the need Delivery: Low uptake of second-line for second and third line well as new regimens; almost no uptake of treatment, and feasibility of formulations, regimens in LICs. testing and switching in LICs. dosage forms, or The project aimed to provide strengths of existing lessons learned and best medicines that practices to WHO for will improve incorporation into Treatment treatment of 2.0 guidance. HIV/AIDS and
2013-16 C.1: Unitaid 2013-2016 Strategic Objectives and grant relevance Strategic objective Market shortcoming sought to be addressed through the project Description of project aims and alignment with Strategic Objective/ market shortcoming 1: Increase access to simple, diagnostics for HIV/AIDS, TB, and malaria Affordability: Traditional HIV diagnostics performed in sophisticated laboratory settings are unaffordable for settings. Quality Absence of information on quality of newer POC diagnostics. Acceptability/ Adaptability: Traditional, laboratory-based products are ill-adapted for low-resource settings because they are complicated to use and maintain, and require sophisticated infrastructure and skilled technicians. Newer POC diagnostics currently on the market allow for more decentralized testing but many are still too complicated for use in remote settings by unskilled workers. Delivery: Slow and insufficient uptake of both traditional laboratory-based and newer POC diagnostics. Within the project aims, operational research was to be conducted on feasibility, acceptability, sustainability, and affordability of POC testing and laboratory-based tools to determine optimal implementation approaches across a range of settings. In addition, informal assessments on the quality of the products were to be conducted. As such, the focus of the project was on acceptability/ adaptability and delivery, although it also touched upon affordability and quality. 2: Increase access to affordable, adapted paediatric medicines to HIV/AIDS, tuberculosis, and malaria Delivery: Few children are initiated on HIV treatment to 18 months of age as recommended. Project indirectly contributed towards this objective by aiming to improve access to EID. 3: Increase access to emerging medicines and/or regimens as well as new formulations, dosage forms, or strengths of existing medicines that will improve treatment of HIV/AIDS and Affordability: High prices of existing products Delivery: Low uptake of second-line regimens; almost no uptake of regimens in LICs. Project indirectly contributed to this objective by increasing the understanding of the need for second and third line treatment, and feasibility of testing and switching in LICs. The project aimed to provide lessons learned and best practices to WHO for incorporation into Treatment 2.0 guidance.
CEPA-evaluation-report_UNITAID-MSF-Grant-20180529_FINAL.docx